
Page#1
JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
At December 30, 2018 and December 31, 2017
(Dollars in Millions Except Share and Per Share Amounts) (Note 1)
2018 2017
Assets
Current assets
Cash and cash equivalents (Notes 1 and 2) $18,107 17,824
Marketable securities (Notes 1 and 2) 1,580 472
Accounts receivable trade, less allowances for doubtful accounts $248 (2017, $291) 14,098 13,490
Inventories (Notes 1 and 3) 8,599 8,765
Prepaid expenses and other receivables 2,699 2,537
Assets held for sale (Note 20) 950 —
Total current assets 46,033 43,088
Property, plant and equipment, net (Notes 1 and 4) 17,035 17,005
Intangible assets, net (Notes 1 and 5) 47,611 53,228
Goodwill (Notes 1 and 5) 30,453 31,906
Deferred taxes on income (Note 8) 7,640 7,105
Other assets 4,182 4,971
Total assets $152,954 157,303
Liabilities and Shareholders’ Equity
Current liabilities
Loans and notes payable (Note 7) $2,796 3,906
Accounts payable 7,537 7,310
Accrued liabilities 7,601 7,304
Accrued rebates, returns and promotions 9,380 7,210
Accrued compensation and employee related obligations 3,098 2,953
Accrued taxes on income (Note 8) 818 1,854
Total current liabilities 31,230 30,537
Long-term debt (Note 7) 27,684 30,675
Deferred taxes on income (Note 8) 7,506 8,368
Employee related obligations (Notes 9 and 10) 9,951 10,074
Long-term taxes payable (Note 8) 8,242 8,472
Other liabilities 8,589 9,017
Total liabilities 93,202 97,143
Shareholders’ equity
Preferred stock — without par value (authorized and unissued 2,000,000 shares) — —
Common stock — par value $1.00 per share (Note 12) (authorized 4,320,000,000 shares; issued
3,119,843,000 shares) 3,120 3,120
Accumulated other comprehensive income (loss) (Note 13) (15,222) (13,199)
Retained earnings 106,216 101,793
94,114 91,714
Less: common stock held in treasury, at cost (Note 12) (457,519,000 shares and 437,318,000 shares) 34,362 31,554
Total shareholders’ equity 59,752 60,160
Total liabilities and shareholders’ equity $152,954 157,303
See Notes to Consolidated Financial Statements
36 • Johnson & Johnson 2018 Annual Report
Page#2
JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
(Dollars and Shares in Millions Except Per Share Amounts) (Note 1)*
2018 2017 2016
Sales to customers $81,581 76,450 71,890
Cost of products sold 27,091 25,439 21,789
Gross profit 54,490 51,011 50,101
Selling, marketing and administrative expenses 22,540 21,520 20,067
Research and development expense 10,775 10,594 9,143
In-process research and development 1,126 408 29
Interest income (611) (385) (368)
Interest expense, net of portion capitalized (Note 4) 1,005 934 726
Other (income) expense, net 1,405 (42) 210
Restructuring (Note 22) 251 309 491
Earnings before provision for taxes on income 17,999 17,673 19,803
Provision for taxes on income (Note 8) 2,702 16,373 3,263
Net earnings $15,297 1,300 16,540
Net earnings per share (Notes 1 and 15)
Basic $5.70 0.48 6.04
Diluted $5.61 0.47 5.93
Average shares outstanding (Notes 1 and 15)
Basic 2,681.5 2,692.0 2,737.3
Diluted 2,728.7 2,745.3 2,788.9
*Prior years amounts were reclassified to conform to current year presentation (adoption of ASU 2017-07)
See Notes to Consolidated Financial Statements
Johnson & Johnson 2018 Annual Report • 37
Page#3
JOHNSON & JOHNSON AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in Millions) (Note 1)
2018 2017 2016
Cash flows from operating activities
Net earnings $15,297 1,300 16,540
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles 6,929 5,642 3,754
Stock based compensation 978 962 878
Asset write-downs 1,258 795 283
Gain on sale of assets/businesses (1,217) (1,307) (563)
Deferred tax provision (1,016) 2,406 (341)
Accounts receivable allowances (31) 17 (11)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable (1,185) (633) (1,065)
(Increase)/Decrease in inventories (644) 581 (249)
Increase in accounts payable and accrued liabilities 3,951 2,725 656
Increase in other current and non-current assets (275) (411) (529)
(Decrease)/Increase in other current and non-current liabilities (1,844) 8,979 (586)
Net cash flows from operating activities 22,201 21,056 18,767
Cash flows from investing activities
Additions to property, plant and equipment (3,670) (3,279) (3,226)
Proceeds from the disposal of assets/businesses, net 3,203 1,832 1,267
Acquisitions, net of cash acquired (Note 20) (899) (35,151) (4,509)
Purchases of investments (5,626) (6,153) (33,950)
Sales of investments 4,289 28,117 35,780
Other (primarily intangibles) (464) (234) (123)
Net cash used by investing activities (3,167) (14,868) (4,761)
Cash flows from financing activities
Dividends to shareholders (9,494) (8,943) (8,621)
Repurchase of common stock (5,868) (6,358) (8,979)
Proceeds from short-term debt 80 869 111
Retirement of short-term debt (2,479) (1,330) (2,017)
Proceeds from long-term debt, net of issuance costs 5 8,992 12,004
Retirement of long-term debt (1,555) (1,777) (2,223)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net 949 1,062 1,189
Other (148) (188) (15)
Net cash used by financing activities (18,510) (7,673) (8,551)
Effect of exchange rate changes on cash and cash equivalents (241) 337 (215)
Increase/(Decrease) in cash and cash equivalents 283 (1,148) 5,240
Cash and cash equivalents, beginning of year (Note 1) 17,824 18,972 13,732
Cash and cash equivalents, end of year (Note 1) $18,107 17,824 18,972
Supplemental cash flow data
Cash paid during the year for:
Interest $1,049 960 730
Interest, net of amount capitalized 963 866 628
Income taxes 4,570 3,312 2,843
Supplemental schedule of non-cash investing and financing activities
Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee
withholding tax on stock awards $2,095 2,062 2,043
Conversion of debt 6 16 35
Acquisitions
Fair value of assets acquired $1,047 36,937 4,586
Fair value of liabilities assumed and noncontrolling interests (148) (1,786) (77)
Net cash paid for acquisitions $899 35,151 4,509
See Notes to Consolidated Financial Statements
40 • Johnson & Johnson 2018 Annual Report